Alkermes Stock Price, News & Analysis (NASDAQ:ALKS)

$52.32 0.17 (0.33 %)
(As of 12/13/2017 01:54 PM ET)
Previous Close$52.15
Today's Range$51.09 - $52.41
52-Week Range$46.42 - $63.40
Volume824,693 shs
Average Volume846,779 shs
Market Capitalization$8.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.14

About Alkermes (NASDAQ:ALKS)

Alkermes logoAlkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALKS
CUSIPG0176710
Phone353-1772-8000

Debt

Debt-to-Equity Ratio0.23%
Current Ratio3.05%
Quick Ratio2.72%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$745.69 million
Price / Sales10.79
Cash FlowN/A
Price / CashN/A
Book Value$7.96 per share
Price / Book6.57

Profitability

Trailing EPS($1.11)
Net Income$-208,440,000.00
Net Margins-20.12%
Return on Equity-7.27%
Return on Assets-5.05%

Miscellaneous

Employees1,750
Outstanding Shares153,780,000

Alkermes (NASDAQ:ALKS) Frequently Asked Questions

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

How were Alkermes' earnings last quarter?

Alkermes PLC (NASDAQ:ALKS) posted its earnings results on Thursday, October, 26th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.01) by $0.04. The company earned $217.40 million during the quarter, compared to analyst estimates of $231.29 million. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The company's revenue for the quarter was up 20.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.09) EPS. View Alkermes' Earnings History.

When will Alkermes make its next earnings announcement?

Alkermes is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Alkermes.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes updated its FY17 earnings guidance on Thursday, October, 26th. The company provided earnings per share guidance of ($0.10) - $0.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.04). The company issued revenue guidance of $850-880 million, compared to the consensus revenue estimate of $893.66 million.

Where is Alkermes' stock going? Where will Alkermes' stock price be in 2017?

10 brokerages have issued 12-month price objectives for Alkermes' stock. Their forecasts range from $50.00 to $81.00. On average, they anticipate Alkermes' share price to reach $64.50 in the next year. View Analyst Ratings for Alkermes.

What are Wall Street analysts saying about Alkermes stock?

Here are some recent quotes from research analysts about Alkermes stock:

  • 1. According to Zacks Investment Research, "Alkermes posted narrower-than-expected loss in the second quarter of 2017 while sales marginally surpassed estimates. Vivitrol and Aristada are anticipated to be primary growth drivers. While, Vivitrol should benefit from the newly passed legislation, CARA, securing reimbursement and access for Aristada also bodes well. The company also plans to submit a new drug application (NDA) for ALKS 5461 in major depressive disorder and expects to complete the pivotal efficacy of ALKS3831 in schizophrenia. However, Alkermes is highly dependent on manufacturing and/or royalty revenues on sales of products that are commercialized by the company’s partners. Given its history of pipeline setbacks, any obstacle in the process of development of the candidates could weigh heavily on the stock. Stiff competition and dependence on partners remains a threat. Moreover, Alkermes’ shares have underperformed the Zacks classified industry year to date." (8/2/2017)
  • 2. Cowen Inc analysts commented, "ALKS reported Q1:17 results which came in below expectations." (4/28/2017)
  • 3. Cantor Fitzgerald analysts commented, "We remain cautious on ALKS stock because we believe it reasonable that the company may not be able to file for regulatory approval of ALKS 5461 (for treating major depressive disorder, MDD) with data from only one positive Phase 3 trial from the three studies that comprise the FORWARD clinical program. We also remain unconvinced that the company will successfully transition from a developer of drug formulation technologies (historically applied to partner's assets) to a developer of proprietary products. As noted in a report we recently published on the evolving multiple sclerosis (MS) landscape, we believe new market entrants could challenge existing drug franchises, in particular that of Biogen (BIIB, Neutral, $277). Even if ALKS 8700 does not reduce GI side effects relative to that experienced with Tecfidera, we believe ALKS would likely seek approval anyway given the hegemony BIIB enjoys in the MS fumarate drug market." (3/16/2017)

Who are some of Alkermes' key competitors?

Who are Alkermes' key executives?

Alkermes' management team includes the folowing people:

  • Richard F. Pops, Chairman, President, and CEO
  • James M. (Jim) Frates, SVP, CFO, and Treasurer
  • Gordon G. Pugh, SVP, COO, and Chief Risk Officer
  • Richard F. Pops, Chairman of the Board, Chief Executive Officer (Age 55)
  • Shane M. Cooke, President (Age 54)
  • James M. Frates, Chief Financial Officer, Senior Vice President, Treasurer (Age 49)
  • Kathryn L. Biberstein, Executive Vice President, Chief Administrative Officer, Chief Compliance Officer, Chief Risk Officer, Secretary (Age 58)
  • Elliot W. Ehrich M.D., Executive Vice President - Research and Development and Chief Medical Officer (Age 57)
  • Iain M. Brown, Senior Vice President - Finance, Chief Accounting Officer (Age 48)
  • David Joseph Gaffin, Senior Vice President, Chief Legal Officer (Age 45)

Who owns Alkermes stock?

Alkermes' stock is owned by many different of institutional and retail investors. Top institutional investors include PRIMECAP MANAGEMENT COMPANY (11.35%), Woodford Investment Management Ltd (4.77%), Thornburg Investment Management Inc. (1.81%), Janus Henderson Group PLC (1.72%), Bank of New York Mellon Corp (0.90%) and Frontier Capital Management Co. LLC (0.51%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Elliot Ehrich, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Institutional Ownership Trends for Alkermes.

Who sold Alkermes stock? Who is selling Alkermes stock?

Alkermes' stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Woodford Investment Management Ltd, First Trust Advisors LP, Frontier Capital Management Co. LLC, State of Wisconsin Investment Board, Canada Pension Plan Investment Board, Granahan Investment Management Inc. MA and California State Teachers Retirement System. Company insiders that have sold Alkermes company stock in the last year include David Joseph Gaffin, Elliot Ehrich, Gordon G Pugh, James M Frates, Kathryn L Biberstein, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Insider Buying and Selling for Alkermes.

Who bought Alkermes stock? Who is buying Alkermes stock?

Alkermes' stock was acquired by a variety of institutional investors in the last quarter, including Thornburg Investment Management Inc., Janus Henderson Group PLC, Asset Management One Co. Ltd., Los Angeles Capital Management & Equity Research Inc., AXA, WINTON GROUP Ltd, Russell Investments Group Ltd. and Ameriprise Financial Inc.. View Insider Buying and Selling for Alkermes.

How do I buy Alkermes stock?

Shares of Alkermes can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alkermes' stock price today?

One share of Alkermes stock can currently be purchased for approximately $52.32.

How big of a company is Alkermes?

Alkermes has a market capitalization of $8.02 billion and generates $745.69 million in revenue each year. The company earns $-208,440,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. Alkermes employs 1,750 workers across the globe.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]


MarketBeat Community Rating for Alkermes (ALKS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  336 (Vote Outperform)
Underperform Votes:  261 (Vote Underperform)
Total Votes:  597
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alkermes (NASDAQ:ALKS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.552.602.55
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $64.50$64.00$63.40$60.91
Price Target Upside: 28.08% upside28.39% upside25.74% upside2.42% upside

Alkermes (NASDAQ:ALKS) Consensus Price Target History

Price Target History for Alkermes (NASDAQ:ALKS)

Alkermes (NASDAQ:ALKS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/28/2017Credit Suisse GroupSet Price TargetBuy$66.00MediumView Rating Details
10/27/2017J P Morgan Chase & CoSet Price TargetBuy$78.00N/AView Rating Details
10/26/2017BarclaysSet Price TargetHold$50.00N/AView Rating Details
10/26/2017CitigroupSet Price TargetHold$62.00N/AView Rating Details
10/21/2017MizuhoSet Price TargetBuy$81.00N/AView Rating Details
8/25/2017Jefferies GroupSet Price TargetBuy$69.00LowView Rating Details
6/13/2017Leerink SwannDowngradeOutperform -> Market Perform$68.00 -> $61.00MediumView Rating Details
4/28/2017CowenReiterated RatingBuyLowView Rating Details
4/24/2017Morgan StanleyReiterated RatingEqual Weight$62.00LowView Rating Details
3/16/2017Cantor FitzgeraldReiterated RatingNeutral$51.00MediumView Rating Details
5/26/2016Evercore ISIInitiated CoverageBuy$59.00N/AView Rating Details
2/22/2016Goldman Sachs GroupLower Price Target$57.00 -> $35.00N/AView Rating Details
1/21/2016GuggenheimReiterated RatingHoldN/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Alkermes (NASDAQ:ALKS) Earnings History and Estimates Chart

Earnings by Quarter for Alkermes (NASDAQ:ALKS)

Alkermes (NASDAQ ALKS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/13/2018$0.13N/AView Earnings Details
10/26/20179/30/2017($0.01)$0.03$231.29 million$217.40 millionViewN/AView Earnings Details
7/27/20176/30/2017($0.01)$0.01$216.54 million$218.80 millionViewN/AView Earnings Details
4/27/20173/31/2017($0.24)($0.31)$195.79 million$191.80 millionViewN/AView Earnings Details
2/15/2017Q416$0.04$0.15$206.38 million$213.50 millionViewListenView Earnings Details
11/2/2016Q316($0.06)($0.09)$186.39 million$180.20 millionViewListenView Earnings Details
7/28/2016Q216($0.10)($0.01)$174.15 million$195.20 millionViewListenView Earnings Details
4/28/2016Q116($0.20)($0.16)$153.64 million$156.80 millionViewListenView Earnings Details
2/25/2016Q415($0.18)($0.15)$161.24 million$163.10 millionViewListenView Earnings Details
10/29/2015Q315($0.21)($0.18)$151.77 million$152.70 millionViewListenView Earnings Details
7/30/2015Q215($0.10)($0.09)$142.80 million$151.40 millionViewListenView Earnings Details
4/30/2015Q115($0.03)$0.06$146.60 million$161.20 millionViewListenView Earnings Details
2/24/2015Q414$0.04$0.11$161.70 million$175.20 millionViewListenView Earnings Details
10/29/2014Q314($0.12)($0.13)$155.53 million$160.00 millionViewListenView Earnings Details
7/31/2014Q314$0.04($0.01)$146.91 million$153.40 millionViewListenView Earnings Details
4/30/2014Q1$0.10$0.11$135.79 million$130.21 millionViewListenView Earnings Details
2/27/2014Q114$0.20$0.27$142.93 million$154.50 millionViewListenView Earnings Details
10/31/2013$0.22$0.22$137.35 million$139.80 millionViewListenView Earnings Details
7/25/2013Q1 2014$0.22$0.30$131.50 million$138.60 millionViewListenView Earnings Details
5/23/2013Q4 2013$0.17$0.40$128.01 million$163.40 millionViewListenView Earnings Details
1/31/2013Q3 2013$0.23$0.34$130.81 million$135.90 millionViewListenView Earnings Details
11/1/2012Q213$0.11$0.17$121.62 million$124.00 millionViewN/AView Earnings Details
7/26/2012$0.16$0.39ViewN/AView Earnings Details
5/17/2012($0.16)($0.14)ViewN/AView Earnings Details
2/2/2012($0.21)($0.11)ViewN/AView Earnings Details
11/3/2011($0.10)($0.22)ViewN/AView Earnings Details
8/1/2011($0.11)$0.02ViewN/AView Earnings Details
5/18/2011($0.14)($0.14)ViewN/AView Earnings Details
2/3/2011($0.15)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Alkermes (NASDAQ:ALKS) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.16)($0.16)($0.16)
Q3 20171($0.15)($0.15)($0.15)
Q4 20172($0.10)($0.05)($0.08)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alkermes (NASDAQ:ALKS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Alkermes (NASDAQ ALKS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.34%
Institutional Ownership Percentage: 99.69%
Insider Trades by Quarter for Alkermes (NASDAQ:ALKS)
Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Alkermes (NASDAQ ALKS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2017Paul J MitchellDirectorSell1,000$51.98$51,980.00View SEC Filing  
11/29/2017James M FratesSVPSell20,932$50.51$1,057,275.32View SEC Filing  
11/8/2017James M. FratesSVPSell20,932$47.58$995,944.56View SEC Filing  
11/2/2017Richard F PopsDirectorSell50,000$48.87$2,443,500.00View SEC Filing  
11/1/2017Michael J LandineSVPSell15,000$48.71$730,650.00View SEC Filing  
10/2/2017Paul J MitchellDirectorSell1,500$50.64$75,960.00View SEC Filing  
9/11/2017Kathryn L BibersteinCAOSell13,566$51.29$695,800.14View SEC Filing  
9/1/2017Paul J MitchellDirectorSell1,500$50.77$76,155.00View SEC Filing  
8/1/2017Paul J MitchellDirectorSell1,500$54.91$82,365.00View SEC Filing  
7/3/2017Paul J MitchellDirectorSell1,500$58.11$87,165.00View SEC Filing  
6/8/2017Shane CookeInsiderSell10,000$60.33$603,300.00View SEC Filing  
6/1/2017Paul J MitchellDirectorSell1,500$57.49$86,235.00View SEC Filing  
5/24/2017Richard F PopsDirectorSell25,000$57.42$1,435,500.00View SEC Filing  
5/18/2017Michael J LandineSVPSell10,000$57.23$572,300.00View SEC Filing  
5/17/2017Richard F PopsDirectorSell50,000$58.19$2,909,500.00View SEC Filing  
5/11/2017Michael J LandineSVPSell10,000$57.01$570,100.00View SEC Filing  
5/10/2017Richard F PopsDirectorSell25,000$57.29$1,432,250.00View SEC Filing  
5/4/2017Shane CookeInsiderSell6,500$60.05$390,325.00View SEC Filing  
4/17/2017Elliot EhrichCMOSell10,000$56.60$566,000.00View SEC Filing  
4/3/2017Kathryn L BibersteinCAOSell15,000$57.68$865,200.00View SEC Filing  
4/3/2017Paul J MitchellDirectorSell1,500$58.31$87,465.00View SEC Filing  
3/29/2017Shane CookeInsiderSell2,070$60.00$124,200.00View SEC Filing  
3/23/2017Shane CookeInsiderSell6,030$60.01$361,860.30View SEC Filing  
3/21/2017Shane CookeInsiderSell1,900$60.09$114,171.00View SEC Filing  
3/20/2017Shane CookeInsiderSell300$60.00$18,000.00View SEC Filing  
3/15/2017Elliot EhrichCMOSell11,000$56.74$624,140.00View SEC Filing  
3/7/2017James M FratesSVPSell25,000$59.08$1,477,000.00View SEC Filing  
3/2/2017Robert A BreyerDirectorSell4,000$60.00$240,000.00View SEC Filing  
3/2/2017Shane CookeInsiderSell20,000$60.00$1,200,000.00View SEC Filing  
3/1/2017Paul J MitchellDirectorSell1,500$57.06$85,590.00View SEC Filing  
2/16/2017Elliot EhrichCMOSell11,000$56.68$623,480.00View SEC Filing  
2/1/2017Paul J MitchellDirectorSell1,500$54.45$81,675.00View SEC Filing  
1/17/2017Elliot EhrichCMOSell11,983$54.32$650,916.56View SEC Filing  
1/9/2017Mark StejbachSVPSell547$60.27$32,967.69View SEC Filing  
1/9/2017Shane CookeInsiderSell550$60.27$33,148.50View SEC Filing  
1/6/2017Elliot EhrichCMOSell10,000$59.44$594,400.00View SEC Filing  
1/6/2017Mark StejbachSVPSell9,453$60.05$567,652.65View SEC Filing  
1/6/2017Shane CookeInsiderSell9,450$60.06$567,567.00View SEC Filing  
1/4/2017Robert A BreyerDirectorSell4,000$60.00$240,000.00View SEC Filing  
1/3/2017David Joseph GaffinSVPSell2,500$55.40$138,500.00View SEC Filing  
1/3/2017Paul J MitchellDirectorSell1,500$55.40$83,100.00View SEC Filing  
12/16/2016Gordon G PughCOOSell21,458$57.65$1,237,053.70View SEC Filing  
12/15/2016Elliot EhrichCMOSell5,000$55.99$279,950.00View SEC Filing  
12/14/2016James M FratesSVPSell25,000$54.73$1,368,250.00View SEC Filing  
12/12/2016Elliot EhrichCMOSell16,983$55.15$936,612.45View SEC Filing  
12/8/2016Kathryn L BibersteinCAOSell14,145$56.13$793,958.85View SEC Filing  
12/7/2016James M. FratesSVPSell23,731$56.28$1,335,580.68View SEC Filing  
12/1/2016Kathryn L BibersteinCAOSell15,000$56.13$841,950.00View SEC Filing  
11/30/2016Michael J LandineSVPSell10,000$57.51$575,100.00View SEC Filing  
11/29/2016Richard F PopsDirectorSell30,000$56.98$1,709,400.00View SEC Filing  
11/22/2016Richard F PopsDirectorSell30,000$58.66$1,759,800.00View SEC Filing  
10/4/2016Paul J MitchellDirectorSell2,000$47.42$94,840.00View SEC Filing  
9/22/2016Elliot EhrichCMOSell5,000$50.83$254,150.00View SEC Filing  
9/16/2016Elliot EhrichCMOSell5,000$48.87$244,350.00View SEC Filing  
9/6/2016David Joseph GaffinSVPSell2,382$45.92$109,381.44View SEC Filing  
9/6/2016Elliot EhrichCMOSell10,000$46.02$460,200.00View SEC Filing  
9/6/2016Iain Michael BrownCAOSell29,976$45.92$1,376,497.92View SEC Filing  
9/6/2016Paul J MitchellDirectorSell2,000$45.92$91,840.00View SEC Filing  
8/4/2016Paul J MitchellDirectorSell2,000$49.48$98,960.00View SEC Filing  
7/27/2016Elliot EhrichCMOSell35,199$51.95$1,828,588.05View SEC Filing  
7/5/2016Paul J MitchellDirectorSell2,000$45.81$91,620.00View SEC Filing  
6/6/2016Paul J MitchellDirectorSell2,000$44.98$89,960.00View SEC Filing  
5/4/2016Paul J MitchellDirectorSell2,000$38.60$77,200.00View SEC Filing  
4/20/2016Michael J LandineSVPSell16,875$41.09$693,393.75View SEC Filing  
4/19/2016Richard F PopsCEOSell18,750$40.15$752,812.50View SEC Filing  
4/18/2016Iain Michael BrownCAOSell5,368$39.27$210,801.36View SEC Filing  
4/13/2016Elliot EhrichCMOSell11,698$37.66$440,546.68View SEC Filing  
4/12/2016Richard F PopsCEOSell25,000$37.79$944,750.00View SEC Filing  
4/4/2016Paul J MitchellDirectorSell2,000$35.65$71,300.00View SEC Filing  
3/22/2016Richard F PopsCEOSell25,000$31.77$794,250.00View SEC Filing  
3/15/2016Richard F PopsCEOSell25,000$31.40$785,000.00View SEC Filing  
3/4/2016Paul J MitchellDirectorSell2,000$32.80$65,600.00View SEC Filing  
3/3/2016David W AnsticeDirectorBuy5,000$32.87$164,350.00View SEC Filing  
2/4/2016Paul J. MitchellDirectorSell2,000$32.81$65,620.00View SEC Filing  
1/4/2016Robert A BreyerDirectorSell2,000$77.33$154,660.00View SEC Filing  
12/28/2015Mark StejbachinsiderSell10,000$80.24$802,400.00View SEC Filing  
12/23/2015Shane CookeinsiderSell18,000$77.23$1,390,140.00View SEC Filing  
12/7/2015Michael J. LandineSVPSell3,750$73.02$273,825.00View SEC Filing  
12/7/2015Richard F. PopsCEOSell37,500$72.06$2,702,250.00View SEC Filing  
12/1/2015Mark StejbachinsiderSell18,000$72.18$1,299,240.00View SEC Filing  
12/1/2015Michael J. LandineSVPSell10,000$72.18$721,800.00View SEC Filing  
12/1/2015Richard F. PopsCEOSell50,000$72.29$3,614,500.00View SEC Filing  
12/1/2015Robert A BreyerDirectorSell2,000$73.46$146,920.00View SEC Filing  
11/23/2015Shane CookeinsiderSell18,000$72.62$1,307,160.00View SEC Filing  
11/2/2015Mark StejbachinsiderSell18,000$72.06$1,297,080.00View SEC Filing  
11/2/2015Robert A BreyerDirectorSell2,000$71.80$143,600.00View SEC Filing  
10/29/2015Iain Michael BrownCAOSell10,822$69.99$757,431.78View SEC Filing  
10/23/2015Shane CookeinsiderSell18,000$62.03$1,116,540.00View SEC Filing  
10/13/2015James M. FratesCFOSell20,000$59.78$1,195,600.00View SEC Filing  
10/2/2015Robert A. BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  
9/23/2015Shane CookeinsiderSell18,000$67.09$1,207,620.00View SEC Filing  
9/17/2015Michael J. LandineSVPSell10,000$71.20$712,000.00View SEC Filing  
9/17/2015Richard F. PopsCEOSell50,000$71.27$3,563,500.00View SEC Filing  
9/15/2015James M. FratesCFOSell20,000$71.10$1,422,000.00View SEC Filing  
9/10/2015Michael J. LandineSVPSell10,000$67.61$676,100.00View SEC Filing  
9/10/2015Richard F. PopsCEOSell50,000$67.57$3,378,500.00View SEC Filing  
9/1/2015Robert A BreyerDirectorSell2,000$61.43$122,860.00View SEC Filing  
8/24/2015Shane CookeinsiderSell18,000$57.65$1,037,700.00View SEC Filing  
7/23/2015Shane CookeInsiderSell18,000$69.79$1,256,220.00View SEC Filing  
7/20/2015Gordon G PughCOOSell18,750$70.10$1,314,375.00View SEC Filing  
7/14/2015James M FratesCFOSell20,000$65.79$1,315,800.00View SEC Filing  
7/1/2015Gordon G PughCOOSell13,750$65.13$895,537.50View SEC Filing  
7/1/2015Robert A BreyerDirectorSell2,000$64.90$129,800.00View SEC Filing  
6/23/2015Shane CookeInsiderSell18,000$66.84$1,203,120.00View SEC Filing  
6/17/2015Paul J MitchellDirectorSell15,500$65.10$1,009,050.00View SEC Filing  
6/16/2015Gordon G PughCOOSell32,977$63.11$2,081,178.47View SEC Filing  
6/16/2015James M FratesCFOSell10,000$58.63$586,300.00View SEC Filing  
6/1/2015Paul J MitchellDirectorSell1,500$60.78$91,170.00View SEC Filing  
6/1/2015Rebecca PetersonSVPSell21,983$60.05$1,320,079.15View SEC Filing  
5/26/2015Rebecca PetersonSVPSell1,322$60.49$79,967.78View SEC Filing  
5/26/2015Shane CookeInsiderSell18,000$60.31$1,085,580.00View SEC Filing  
5/22/2015Rebecca PetersonSVPSell28,558$61.71$1,762,314.18View SEC Filing  
5/12/2015James M FratesCFOSell10,000$59.34$593,400.00View SEC Filing  
5/4/2015Robert A BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  
5/1/2015Paul J MitchellDirectorSell1,500$55.79$83,685.00View SEC Filing  
4/23/2015Shane CookeInsiderSell18,000$62.55$1,125,900.00View SEC Filing  
4/21/2015Elliot EhrichCMOSell25,000$62.39$1,559,750.00View SEC Filing  
4/15/2015Gordon G PughCOOSell13,750$63.21$869,137.50View SEC Filing  
4/15/2015James M FratesCFOSell10,000$62.42$624,200.00View SEC Filing  
4/15/2015Paul J MitchellDirectorSell1,500$62.71$94,065.00View SEC Filing  
4/1/2015Robert A BreyerDirectorSell5,000$61.22$306,100.00View SEC Filing  
3/23/2015Shane CookeInsiderSell18,000$65.33$1,175,940.00View SEC Filing  
3/16/2015Elliot EhrichCMOSell18,000$66.81$1,202,580.00View SEC Filing  
3/10/2015James M FratesCFOSell10,000$66.25$662,500.00View SEC Filing  
3/5/2015Rebecca PetersonSVPSell17,737$71.37$1,265,889.69View SEC Filing  
3/2/2015Gordon G PughCOOSell15,000$71.39$1,070,850.00View SEC Filing  
3/2/2015Robert A BreyerDirectorSell5,000$70.86$354,300.00View SEC Filing  
2/23/2015Shane CookeInsiderSell18,000$74.29$1,337,220.00View SEC Filing  
2/17/2015Elliot EhrichCMOSell18,000$70.87$1,275,660.00View SEC Filing  
2/3/2015James M FratesCFOSell10,000$70.83$708,300.00View SEC Filing  
2/2/2015Gordon G PughCOOSell15,000$72.01$1,080,150.00View SEC Filing  
2/2/2015Robert A BreyerDirectorSell5,000$72.91$364,550.00View SEC Filing  
1/26/2015Gordon G PughCOOSell15,000$70.02$1,050,300.00View SEC Filing  
1/23/2015Shane CookeInsiderSell118,000$69.13$8,157,340.00View SEC Filing  
1/16/2015Floyd E BloomDirectorSell20,000$67.12$1,342,400.00View SEC Filing  
1/15/2015Elliot EhrichCMOSell18,375$66.45$1,221,018.75View SEC Filing  
1/15/2015James M FratesCFOSell10,000$66.86$668,600.00View SEC Filing  
1/7/2015Kathryn L BibersteinSVPSell28,374$65.00$1,844,310.00View SEC Filing  
1/2/2015Robert A BreyerDirectorSell5,000$58.57$292,850.00View SEC Filing  
12/11/2014Richard F PopsCEOSell100,000$56.04$5,604,000.00View SEC Filing  
12/10/2014James M FratesCFOSell18,870$56.07$1,058,040.90View SEC Filing  
12/9/2014Michael J LandineSVPSell18,000$56.82$1,022,760.00View SEC Filing  
12/5/2014Kathryn L BibersteinSVPSell15,433$57.61$889,095.13View SEC Filing  
12/1/2014Robert A BreyerDirectorSell5,000$54.64$273,200.00View SEC Filing  
11/19/2014James M FratesCFOSell8,000$53.86$430,880.00View SEC Filing  
11/13/2014Richard F PopsCEOSell100,000$52.87$5,287,000.00View SEC Filing  
11/7/2014James M FratesCFOSell13,303$49.98$664,883.94View SEC Filing  
11/6/2014Kathryn L BibersteinSVPSell20,000$50.54$1,010,800.00View SEC Filing  
11/3/2014Robert A BreyerDirectorSell5,000$50.05$250,250.00View SEC Filing  
10/23/2014Gordon G PughCOOSell14,577$45.00$655,965.00View SEC Filing  
10/8/2014James M FratesCFOSell16,000$41.00$656,000.00View SEC Filing  
10/1/2014Robert A BreyerDirectorSell5,000$42.59$212,950.00View SEC Filing  
9/24/2014James M FratesCFOSell16,000$45.29$724,640.00View SEC Filing  
9/18/2014Michael J LandineSVPSell15,000$45.60$684,000.00View SEC Filing  
9/17/2014Gordon G PughCOOSell14,900$45.04$671,096.00View SEC Filing  
9/17/2014Richard F PopsCEOSell50,000$44.89$2,244,500.00View SEC Filing  
9/10/2014James M FratesCFOSell16,000$43.18$690,880.00View SEC Filing  
9/2/2014Gordon G PughCOOSell1,100$45.08$49,588.00View SEC Filing  
9/2/2014Robert A BreyerDirectorSell5,000$45.12$225,600.00View SEC Filing  
8/27/2014James M FratesCFOSell16,000$45.08$721,280.00View SEC Filing  
8/26/2014Gordon G PughCOOSell16,000$45.00$720,000.00View SEC Filing  
8/13/2014James M FratesCFOSell15,000$41.37$620,550.00View SEC Filing  
8/11/2014Elliot EhrichCMOSell16,667$41.65$694,180.55View SEC Filing  
8/4/2014Gordon G PughCOOSell23,250$43.20$1,004,400.00View SEC Filing  
8/1/2014Robert A BreyerDirectorSell5,000$42.53$212,650.00View SEC Filing  
7/16/2014James M FratesCFOSell8,000$46.50$372,000.00View SEC Filing  
7/9/2014Elliot EhrichCMOSell16,667$47.41$790,182.47View SEC Filing  
7/9/2014James M FratesCFOSell7,000$47.41$331,870.00View SEC Filing  
7/3/2014Michael J LandineSVPSell7,000$51.31$359,170.00View SEC Filing  
7/2/2014Richard F PopsCEOSell50,000$51.69$2,584,500.00View SEC Filing  
7/1/2014Gordon G PughCOOSell16,000$46.49$743,840.00View SEC Filing  
7/1/2014Robert A BreyerDirectorSell5,000$50.57$252,850.00View SEC Filing  
6/26/2014Michael J LandineSVPSell10,000$49.92$499,200.00View SEC Filing  
6/25/2014James M FratesCFOSell7,000$50.22$351,540.00View SEC Filing  
6/25/2014Richard F PopsCEOSell50,000$49.87$2,493,500.00View SEC Filing  
6/20/2014Paul J MitchellDirectorSell17,000$50.00$850,000.00View SEC Filing  
6/19/2014Elliot EhrichCMOSell17,282$47.10$813,982.20View SEC Filing  
6/19/2014Michael J LandineSVPSell10,000$47.01$470,100.00View SEC Filing  
6/18/2014Richard F PopsCEOSell50,000$46.72$2,336,000.00View SEC Filing  
6/17/2014Kathryn L BibersteinSVPSell8,400$47.41$398,244.00View SEC Filing  
6/11/2014James M FratesCFOSell7,000$47.72$334,040.00View SEC Filing  
6/9/2014Elliot EhrichCMOSell16,667$48.15$802,516.05View SEC Filing  
6/2/2014Gordon G PughCOOSell16,000$45.34$725,440.00View SEC Filing  
6/2/2014Robert A BreyerDirectorSell5,000$45.18$225,900.00View SEC Filing  
5/30/2014Rebecca PetersonSVPSell21,981$45.86$1,008,048.66View SEC Filing  
5/23/2014Rebecca PetersonSVPSell1,321$45.08$59,550.68View SEC Filing  
5/22/2014Elliot EhrichCMOSell2,378$44.49$105,797.22View SEC Filing  
5/22/2014Gordon PughCOOSell15,700$45.25$710,425.00View SEC Filing  
5/22/2014Rebecca PetersonSVPSell19,807$44.02$871,904.14View SEC Filing  
5/21/2014Elliot EhrichCMOSell1,981$44.00$87,164.00View SEC Filing  
5/21/2014James FratesCFOSell7,000$44.30$310,100.00View SEC Filing  
5/20/2014Rebecca PetersonSVPSell20,307$44.05$894,523.35View SEC Filing  
5/19/2014Elliot EhrichCMOSell2,206$43.55$96,071.30View SEC Filing  
5/8/2014Floyd BloomDirectorSell10,000$46.16$461,600.00View SEC Filing  
5/5/2014Robert BreyerDirectorSell5,000$46.72$233,600.00View SEC Filing  
5/1/2014Paul MitchellDirectorSell1,000$45.90$45,900.00View SEC Filing  
4/9/2014James FratesCFOSell7,000$42.91$300,370.00View SEC Filing  
4/1/2014Paul MitchellDirectorSell1,500$44.14$66,210.00View SEC Filing  
3/19/2014James FratesCFOSell7,000$46.84$327,880.00View SEC Filing  
3/11/2014Wendy DixonDirectorBuy1,600$47.37$75,792.00View SEC Filing  
3/5/2014James FratesCFOSell7,000$47.78$334,460.00View SEC Filing  
2/18/2014Elliot EhrichCMOSell7,718$52.45$404,809.10View SEC Filing  
2/3/2014Paul MitchellDirectorSell1,500$48.15$72,225.00View SEC Filing  
1/21/2014Elliot EhrichCMOSell7,718$48.61$375,171.98View SEC Filing  
1/16/2014Elliot EhrichCMOSell14,555$47.35$689,179.25View SEC Filing  
1/16/2014Gordon PughCOOSell30,000$47.16$1,414,800.00View SEC Filing  
1/16/2014James FratesCFOSell7,000$47.40$331,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alkermes (NASDAQ ALKS) News Headlines

Source:
DateHeadline
Scott+Scott, Attorneys at Law, LLP Alerts Investors to the Filing of Securities Class Action Against Alkermes plc (ALKS)Scott+Scott, Attorneys at Law, LLP Alerts Investors to the Filing of Securities Class Action Against Alkermes plc (ALKS)
finance.yahoo.com - December 12 at 3:26 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline - January 22, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline - January 22, 2018
finance.yahoo.com - December 12 at 3:26 PM
ALKS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Alkermes plc and a Lead Plaintiff Deadline of January 22, 2018ALKS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Alkermes plc and a Lead Plaintiff Deadline of January 22, 2018
finance.yahoo.com - December 12 at 8:45 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018
finance.yahoo.com - December 11 at 3:25 PM
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Alkermes plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action LawsuitSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Alkermes plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
finance.yahoo.com - December 11 at 3:25 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc of Class Action Lawsuit and Upcoming Deadline – ALKSSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc of Class Action Lawsuit and Upcoming Deadline – ALKS
finance.yahoo.com - December 9 at 9:01 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alkermes plc of Commencement of a Class Action ... - GlobeNewswire (press release)INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alkermes plc of Commencement of a Class Action ... - GlobeNewswire (press release)
globenewswire.com - December 7 at 3:28 PM
Robbins Arroyo LLP: Alkermes plc (ALKS) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)Robbins Arroyo LLP: Alkermes plc (ALKS) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)
www.businesswire.com - December 7 at 3:28 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alkermes plc of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 – ALKSINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alkermes plc of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 – ALKS
finance.yahoo.com - December 7 at 3:28 PM
Surging Earnings Estimates Signal Good News for Alkermes (ALKS)Surging Earnings Estimates Signal Good News for Alkermes (ALKS)
www.zacks.com - December 7 at 8:49 AM
Robbins Arroyo LLP: Alkermes plc (ALKS) Misled Shareholders According to a Recently Filed Class ActionRobbins Arroyo LLP: Alkermes plc (ALKS) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - December 7 at 8:49 AM
Primecap Management Buys Alkermes BiopharmaPrimecap Management Buys Alkermes Biopharma
finance.yahoo.com - December 6 at 3:26 PM
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Alkermes plcThe Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Alkermes plc
finance.yahoo.com - December 5 at 3:26 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline - January 22, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline - January 22, 2018
finance.yahoo.com - December 5 at 3:26 PM
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Alkermes plcThe Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Alkermes plc
finance.yahoo.com - December 5 at 8:50 AM
Alkermes (ALKS) Lifted to "Hold" at ValuEngineAlkermes (ALKS) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - December 4 at 12:22 AM
Alkermes PLC (ALKS) Director Paul J. Mitchell Sells 1,000 SharesAlkermes PLC (ALKS) Director Paul J. Mitchell Sells 1,000 Shares
www.americanbankingnews.com - December 1 at 10:50 PM
ALKS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of ...ALKS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of ...
www.businesswire.com - December 1 at 3:29 PM
Zacks: Analysts Anticipate Alkermes PLC (ALKS) Will Announce Quarterly Sales of $239.12 MillionZacks: Analysts Anticipate Alkermes PLC (ALKS) Will Announce Quarterly Sales of $239.12 Million
www.americanbankingnews.com - December 1 at 3:30 AM
Insider Selling: Alkermes PLC (ALKS) SVP Sells 20,932 Shares of StockInsider Selling: Alkermes PLC (ALKS) SVP Sells 20,932 Shares of Stock
www.americanbankingnews.com - November 30 at 7:52 PM
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Alkermes plc (Nasdaq: ALKS) To Contact Brower Piven Before The Lead Plaintiff DeadlineSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Alkermes plc (Nasdaq: ALKS) To Contact Brower Piven Before The Lead Plaintiff Deadline
finance.yahoo.com - November 30 at 3:26 PM
ALKS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plcALKS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plc
finance.yahoo.com - November 30 at 3:26 PM
Scott+Scott, Attorneys at Law, LLP Alerts Investors to the Filing of a Securities Class Action Against Alkermes plc (ALKS)Scott+Scott, Attorneys at Law, LLP Alerts Investors to the Filing of a Securities Class Action Against Alkermes plc (ALKS)
finance.yahoo.com - November 29 at 3:25 PM
Alkermes PLC (ALKS) Expected to Post Earnings of $0.14 Per ShareAlkermes PLC (ALKS) Expected to Post Earnings of $0.14 Per Share
www.americanbankingnews.com - November 29 at 3:18 PM
Free Research Reports on These Drug Delivery Stocks -- Bio-Path, IntelliPharmaCeutics, Adamis Pharma, and AlkermesFree Research Reports on These Drug Delivery Stocks -- Bio-Path, IntelliPharmaCeutics, Adamis Pharma, and Alkermes
www.prnewswire.com - November 29 at 8:55 AM
Alkermes (ALKS) vs. Momenta Pharmaceuticals (MNTA) Head to Head AnalysisAlkermes (ALKS) vs. Momenta Pharmaceuticals (MNTA) Head to Head Analysis
www.americanbankingnews.com - November 29 at 3:54 AM
Credit Suisse Group Analysts Give Alkermes (ALKS) a $66.00 Price TargetCredit Suisse Group Analysts Give Alkermes (ALKS) a $66.00 Price Target
www.americanbankingnews.com - November 28 at 9:06 AM
Interesting ALKS Put And Call Options For January 2018Interesting ALKS Put And Call Options For January 2018
www.nasdaq.com - November 28 at 8:21 AM
Recent lawsuits claim Alkermes fired female workers who complained of biasRecent lawsuits claim Alkermes fired female workers who complained of bias
finance.yahoo.com - November 28 at 8:20 AM
Why Is Alkermes (ALKS) Down 8.3% Since the Last Earnings Report?Why Is Alkermes (ALKS) Down 8.3% Since the Last Earnings Report?
finance.yahoo.com - November 28 at 8:20 AM
Biogen teams up with Alkermes to develop MS candidate ALKS 8700 - Seeking AlphaBiogen teams up with Alkermes to develop MS candidate ALKS 8700 - Seeking Alpha
seekingalpha.com - November 27 at 3:19 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alkermes plc ... - PR Newswire (press release)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alkermes plc ... - PR Newswire (press release)
www.prnewswire.com - November 27 at 3:19 PM
Biogen boosts multiple sclerosis holding with Alkermes licenseBiogen boosts multiple sclerosis holding with Alkermes license
finance.yahoo.com - November 27 at 3:19 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plcINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plc
finance.yahoo.com - November 27 at 3:19 PM
Is Biogen's Multiple Sclerosis Franchise Getting A New Lease On Life?Is Biogen's Multiple Sclerosis Franchise Getting A New Lease On Life?
finance.yahoo.com - November 27 at 3:19 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline - January 22, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline - January 22, 2018
finance.yahoo.com - November 27 at 3:19 PM
Biogen: If You Cant Beat em…Biogen: If You Can't Beat 'em…
finance.yahoo.com - November 27 at 3:19 PM
Biogen teams up with Alkermes to develop MS candidate ALKS 8700Biogen teams up with Alkermes to develop MS candidate ALKS 8700
www.msn.com - November 27 at 9:57 AM
Biogen In Deal With Alkermes To Develop, Commercialize ALKS 8700 For MSBiogen In Deal With Alkermes To Develop, Commercialize ALKS 8700 For MS
www.nasdaq.com - November 27 at 9:57 AM
Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : November 27, 2017Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : November 27, 2017
finance.yahoo.com - November 27 at 9:57 AM
UPDATE: Alkermes shares rise 6% on Biogen multiple sclerosis drug partnershipUPDATE: Alkermes shares rise 6% on Biogen multiple sclerosis drug partnership
finance.yahoo.com - November 27 at 9:57 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc of Class Action Lawsuit and Upcoming Deadline - ALKSSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc of Class Action Lawsuit and Upcoming Deadline - ALKS
finance.yahoo.com - November 27 at 9:57 AM
Alkermes Jumps on License Deal With Biogen -- Biotech MoversAlkermes Jumps on License Deal With Biogen -- Biotech Movers
finance.yahoo.com - November 27 at 9:57 AM
Stocks to Watch: Amazon, Time, Alkermes, Biogen, SandRidge, Barracuda NetworksStocks to Watch: Amazon, Time, Alkermes, Biogen, SandRidge, Barracuda Networks
finance.yahoo.com - November 27 at 9:57 AM
Pomerantz Law Firm Announces the Filing of a Class Action against Alkermes plc and Certain Officers – ALKS - GlobeNewswire (press release)Pomerantz Law Firm Announces the Filing of a Class Action against Alkermes plc and Certain Officers – ALKS - GlobeNewswire (press release)
globenewswire.com - November 23 at 3:28 PM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Alkermes plc Investors (ALKS)Glancy Prongay & Murray LLP Commences Investigation on Behalf of Alkermes plc Investors (ALKS)
finance.yahoo.com - November 22 at 9:23 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plcSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plc
finance.yahoo.com - November 22 at 4:20 PM
Alkermes Named a Top Place to Work by The Boston GlobeAlkermes Named a Top Place to Work by The Boston Globe
finance.yahoo.com - November 20 at 5:11 PM
Alkermes PLC (ALKS) Receives Average Rating of "Hold" from BrokeragesAlkermes PLC (ALKS) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 20 at 9:00 AM
Alkermes: Bearish Technicals But Several Value Drivers In 2018 - Seeking AlphaAlkermes: Bearish Technicals But Several Value Drivers In 2018 - Seeking Alpha
seekingalpha.com - November 17 at 3:26 PM

SEC Filings

Alkermes (NASDAQ:ALKS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alkermes (NASDAQ:ALKS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alkermes (NASDAQ ALKS) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.